i. To determine the abv3-integrin expression isolated from endometrium tissue from women with RIF prior to medical therapy.~ii. To determine the abv3-integrin expression isolated from endometrium tissue from Group A, Group B and Group C following the medical therapy.~iii. To compare the abv3-integrin expression from endometrium tissue obtained from Group A, B and C following the medical therapy.~iv. To compare the implantation rates among Group A, B and C following the medical therapy.~v. To compare the ongoing pregnancy among Group A, B and C following the medical therapy
To compare the abv3-integrin expression in endometrium tissue among RIF women between the GnRH analogue with Aromatase Inhibitor (Group A) , GnRH analogue with progesterone (Group B) and GnRH analogue alone as control group (Group C)